Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye fluid clues may predict who benefits from vision-saving injections

NCT ID NCT04439708

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study analyzes blood and aqueous humor (eye fluid) from 250 people with type 1 choroidal neovascularization—a cause of vision loss—and from controls without the condition. Researchers measure biomarker levels and check whether they correlate with how well patients respond to anti-VEGF treatment. The goal is to identify biological markers that could guide personalized therapy for this eye disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which patients will respond well to anti-VEGF injections, allowing more personalized treatment for vision loss.
What could go wrong
This is an observational biomarker study, not a treatment trial. It may not find reliable markers, and any findings would need further validation before changing clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Group 1 : patients with type 1 choroidal neovascularization Group 2: patients without choroidal neovascularization before ocular surgery

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients of group 1: * Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration * Patients without intravitreal injection or last intravitreal injection \> 3 months * Informed signed consent Patients of group 2: * Patients without choroidal neovascularization * Patients with intraocular surgery (cataract or vitrectomy surgery) * Signed consent Exclusion Criteria: * Myocardial infarction \< 12 months * Chronic renal failure * Inflammatory disease * Infectious disease :HIV, viral hepatitis, tuberculosis * Type 1 or 2 Diabetes * Patients treated by mineralocorticoid antagonist treatment. * Type 2 or 3 choroidal neovascularization * Pregnant woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Choroidal neovascularization are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central serous chorioretinopathy choroidal neovascularization hyperaldosteronism macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Choroidal neovascularization Mineralocorticoid excess

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Foch

    RECRUITING

    Suresnes, 92150, France

  • Ophtalmopole Hôpital Cochin

    RECRUITING

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.